Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 45Breast Neoplasms 15Leiomyoma 3Cardiovascular Diseases 3Polycystic Ovary Syndrome 2Neoplasms 2Endometrial Neoplasms 2Advanced Breast Cancer 2Stage II Prostate Adenocarcinoma 1Sexual Dysfunctions, Psychological 1Sarcopenia 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms, Castration-Resistant 1Prostatectomy 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Pelvic Pain 1Oligometastatic Prostate Carcinoma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Metabolic Syndrome 1Metabolic Diseases 1Kallmann Syndrome 1Inflammatory Breast Neoplasms 1Infertility 1Hypogonadism 1Hyperprolactinemia 1

Interventions

Magnetic Resonance Spectroscopy 2prednylidene 1gallium 68 PSMA-11 1deltacortene 1apalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stage II Prostate Adenocarcinoma × Gonadotropin-Releasing Hormone × Clear all
NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡